|Bid||118.06 x 500|
|Ask||127.00 x 200|
|Day's Range||120.45 - 124.00|
|52 Week Range||77.58 - 153.15|
|PE Ratio (TTM)||-220.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.
Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
Incyte's consolidated revenues rose ~32.5% to ~$326.4 million in 2Q17, compared with ~$246.3 million in 2Q16.